Theralase Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various...
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-05-20 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference
Marlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-19 7:45 AM EDT | Phio Pharmaceuticals Corp.
medmix Named One of Only Nine Swiss Companies for Climate Leadership
Baar, Switzerland--(Newsfile Corp. - May 19, 2025) - medmix AG Neuhofstrasse 20CH-6430 Baarcommunications@medmix.comwww.medmix.swissMEDIA RELEASE DOWNLOAD MEDIA RELEASEmedmix named one
Technology, Healthcare and Hospitals, Household/Consumer/Cosmetics, Health
2025-05-19 6:19 AM EDT | medmix AG
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that it has granted 600,000 incentive stock options (the "Options") to directors and employees of the company. The Options are exercisable at a...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-16 4:30 PM EDT | NervGen Pharma Corp.
Kovo+ Holdings Inc. Completes Continuance into Alberta
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2025) - Kovo+ Holdings Inc. (TSXV: KOVO) (formerly Kovo HealthTech Corporation) ("Kovo" or the "Company") announces that it has completed a continuance out of the jurisdiction of British Columbia under the Business Corporations Act (British Columbia) and into the jurisdiction of Alberta under...
Technology, Healthcare and Hospitals, Internet Technology
2025-05-16 4:23 PM EDT | Kovo+ Holdings Inc.
CORRECTION FROM SOURCE: Adia Nutrition Inc. Successfully Uplists to OTCQB Venture Market in Record-Breaking Six Weeks and Completes SEC Rule 15c2-11 Compliance
This release corrects and replaces the press release issued by Adia Nutrition Inc., on May 16, 2025, at 8:09 am EDT.Winter Park, Florida--(Newsfile Corp. - May 16, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces its successful uplisting from the OTC...
Healthcare and Hospitals, Health
2025-05-16 10:11 AM EDT | Adia Nutrition Inc.
Adia Nutrition Inc. Files for OTCQB Uplisting with OTC Markets, Emphasizing OTC-Handled 15c2-11 for Transparency and Investor Reach
Winter Park, Florida--(Newsfile Corp. - May 16, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces that it has officially filed with OTC Markets Group for uplisting to the OTCQB Venture Market. This filing follows the successful completion of an independent...
Healthcare and Hospitals, Health
2025-05-16 8:09 AM EDT | Adia Nutrition Inc.
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical studyMarlborough, Massachusetts--(Newsfile Corp. - May 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-15 4:15 PM EDT | Phio Pharmaceuticals Corp.
Discovery Senior Living Invests in New Clinical Technology Platform to Power Scaled, Resident-Centered Growth Across Hundreds of Communities
Bonita Springs, Florida--(Newsfile Corp. - May 15, 2025) - Discovery Senior Living (Discovery or the Company) and its affiliated companies, a leading operator in the seniors housing industry, is pleased to announce a major strategic investment in its clinical technology platform to accelerate scaled growth across its current base of...
Healthcare and Hospitals, Real Estate, Housing
2025-05-15 9:10 AM EDT | Discovery Senior Living
NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates
Completed last subject, last visit in the chronic cohort, data readout targeted for early June 2025Vancouver, British Columbia--(Newsfile Corp. - May 15, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuro-reparative therapeutics, today reported its financial and operational results for the first...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-15 7:30 AM EDT | NervGen Pharma Corp.
Fonar Announces Fiscal 2025 Financial Results for 3rd Quarter and Nine-Month Period
Net Income increased 25% to $3.1 million for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024. Income from Operations for the quarter ended March 31, 2025 decreased 2% to $3.7 million as compared to the quarter ended March 31, 2024. Diluted Net Income...
Technology, Healthcare and Hospitals
2025-05-15 7:00 AM EDT | Fonar Corporation
Newtopia Completes $2 Million Debt Financing, Assignment of Existing Senior Secured Credit Facility and Provides Corporate Update
Existing senior secured credit facility assigned to new investors; added $1.6 million of new senior secured financing, and settled $0.4 million owing to officers and directors for no cash consideration Moving towards cash flow positive status within calendar 2025Supports Newtopia's ability to facilitate sustainable metabolic health outcomes, proven cost savings...
Healthcare and Hospitals, Health
2025-05-14 4:50 PM EDT | Newtopia Inc.
Envoy Medical Achieves Clinical Trial Milestone and is Optimistic About Expansion into Final Stage of Trial
White Bear Lake, Minnesota--(Newsfile Corp. - May 13, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announces achieving the important milestone of successful activation of all 10 study participants' fully implanted...
Biotechnology, Healthcare and Hospitals
2025-05-13 9:15 AM EDT | Envoy Medical, Inc.
Adaptimmune Reports Q1 Financial Results and Provides Business Update
TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced$4.0 million Tecelra net sales in Q1 2025Instituting 2025 Tecelra full year sales guidance of $35-$45 millionLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated in 2026
Biotechnology, Healthcare and Hospitals
2025-05-13 7:30 AM EDT | Adaptimmune Therapeutics PLC
HEALWELL Reports Record Revenue Growth of 208% in Q1-2025 Including Record Growth of 224% in AI and Data Science Revenue
HEALWELL achieved quarterly revenue from continuing operations of $14.1 million in Q1-2025, 208% higher than the $4.6 million generated in Q1-2024. Revenue growth was driven by acquisitions in the past year and record growth of 224% in the Company's AI and Data Science business.On April 1, 2025, HEALWELL completed...
Technology, Healthcare and Hospitals
2025-05-13 6:00 AM EDT | HEALWELL AI
BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced the publication of a pivotal study as part of the special issue Molecular Pathogenesis and Diagnostics of Lung...
Technology, Biotechnology, Healthcare and Hospitals
2025-05-12 8:30 AM EDT | BioMark Diagnostics, Inc.
Kovo+ Holdings Inc. Announces Amendments to Secured Promissory Note
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2025) - Kovo+ Holdings Inc. (formerly Kovo HealthTech Corporation) (TSXV: KOVO) ("Kovo" or the "Company") announces that it has entered into a second amendment agreement (the "Amendment Agreement") with Vantage Business Management Services ("Vantage"), whereby it agreed to make certain amendments to a...
Technology, Healthcare and Hospitals, Internet Technology
2025-05-09 5:17 PM EDT | Kovo+ Holdings Inc.
Sol Global Announces $1M USD Strategic Investment into McQueen Labs Inc. ("MCQ Markets") for Digital Tokenization of Investment-Grade Collector Cars
Toronto, Ontario--(Newsfile Corp. - May 9, 2025) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), one of the first publicly traded companies focused on institutional Solana investments, is pleased to announce a proposed Securities Purchase Agreement (the "Agreement") with McQueen Labs Inc., a...
Healthcare and Hospitals, Pharmaceuticals
2025-05-09 9:07 AM EDT | SOL Global Investments Corp.
BioMark Diagnostics Announces Uplisting to OTCQB Venture Market
Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that its common shares have been officially approved for uplisting from the OTC...
Technology, Biotechnology, Healthcare and Hospitals
2025-05-08 8:30 AM EDT | BioMark Diagnostics, Inc.
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday,...
Biotechnology, Healthcare and Hospitals
2025-05-07 12:00 PM EDT | Adaptimmune Therapeutics PLC